← Leaderboards
Daniel M Sullivan
University Of South Florida
$9,547,844
Attributed
$11,727,484
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2010–19$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$25,561,443 · 13
By mechanism
U54$13,833,959 · 2
N01$4,266,343 · 2
UM1$2,906,187 · 1
P30$2,882,656 · 4
R01$1,672,298 · 1
P20$0 · 1
Top collaborators
- Jaime L Matta15 shared
- Teresita Munoz-Antonia14 shared
- Jose A Torres-Ruiz12 shared
- Steven Grant5 shared
- Amit M Oza5 shared
- Lillian L Siu5 shared
- Julie Dutil3 shared
- Kenneth Lynn Wright1 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Benjamin Djulbegovic$4,463,195
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsResearch PersonnelClinical ResearchCancer CenterResourcesProtocols DocumentationProgramsMalignant NeoplasmsEnsureBaseScienceTranslational ResearchTrainingProceduresServicesLeadCommunity OutreachFacultyCollaborationsFloridaTraining And EducationUnderserved PopulationResearch InfrastructureTechnology
Grant awards (61)
Princess Margaret Phase I Consorium (PMP1C)$529,423
UM1 · FY2019 · CA
Princess Margaret Phase I Consorium (PMP1C)$341,419
UM1 · FY2019 · CA
Clinical Protocol and Data Management Core$229,632
P30 · FY2019 · CA · contact PI
Princess Margaret Phase I Consorium (PMP1C)$99,360
UM1 · FY2019 · CA
Core 017 (502) Protocol Review and Monitoring System$74,976
P30 · FY2019 · CA · contact PI
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership$1,751,252
U54 · FY2018 · CA
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership$1,619,382
U54 · FY2018 · CA
Princess Margaret Phase I Consorium (PMP1C)$932,981
UM1 · FY2018 · CA
CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS$422,372
R01 · FY2018 · CA · contact PI
Clinical Protocol and Data Management Core$249,438
P30 · FY2018 · CA · contact PI
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership$85,299
U54 · FY2018 · CA
Core 017 (502) Protocol Review and Monitoring System$71,712
P30 · FY2018 · CA · contact PI
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership$48,687
U54 · FY2018 · CA
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership$47,040
U54 · FY2018 · CA
Core 017 (502) Protocol Review and Monitoring System$8,050
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management Core$8,050
P30 · FY2018 · CA · contact PI
Core 017 (502) Protocol Review and Monitoring System$3,751
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management Core$3,751
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management Core$3,290
P30 · FY2018 · CA · contact PI
Core 017 (502) Protocol Review and Monitoring System$3,290
P30 · FY2018 · CA · contact PI
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership$1,656,304
U54 · FY2017 · CA
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership$1,427,230
U54 · FY2017 · CA
CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS$422,372
R01 · FY2017 · CA · contact PI
Clinical Protocol and Data Management Core$249,436
P30 · FY2017 · CA · contact PI
Core 017 (502) Protocol Review and Monitoring System$71,710
P30 · FY2017 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$1,413,248
U54 · FY2016 · CA
Princess Margaret Phase I Consorium (PMP1C)$1,003,004
UM1 · FY2016 · CA
CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS$413,777
R01 · FY2016 · CA · contact PI
CLINICAL TRIALS OFFICE$314,813
P30 · FY2016 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$187,377
U54 · FY2016 · CA
PROTOCOL - SPECIFIC RESEARCH SUPPORT$81,205
P30 · FY2016 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$1,418,004
U54 · FY2015 · CA
CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS$413,777
R01 · FY2015 · CA · contact PI
CLINICAL TRIALS OFFICE$314,813
P30 · FY2015 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$124,761
N01 · FY2015 · CA · contact PI
PROTOCOL - SPECIFIC RESEARCH SUPPORT$81,204
P30 · FY2015 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$1,356,154
U54 · FY2014 · CA
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$490,080
N01 · FY2014 · CA · contact PI
CLINICAL TRIALS OFFICE$293,321
P30 · FY2014 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$60,980
U54 · FY2014 · CA
PROTOCOL - SPECIFIC RESEARCH SUPPORT$59,713
P30 · FY2014 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$1,320,610
U54 · FY2013 · CA
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$367,560
N01 · FY2013 · CA · contact PI
CLINICAL TRIALS OFFICE$305,093
P30 · FY2013 · CA · contact PI
PROTOCOL - SPECIFIC RESEARCH SUPPORT$78,699
P30 · FY2013 · CA · contact PI
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$59,181
U54 · FY2013 · CA
Ponce School of Medicine-Moffitt Cancer Center partnership (2/2)$1,383,211
U54 · FY2012 · CA
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$735,120
N01 · FY2012 · CA · contact PI
CLINICAL TRIALS OFFICE$299,462
P30 · FY2012 · CA · contact PI
PROTOCOL - SPECIFIC RESEARCH SUPPORT$77,247
P30 · FY2012 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$661,608
N01 · FY2011 · CA · contact PI
Early Therapuetics with Phase II Emphasis$639,300
N01 · FY2011 · CA · contact PI
Early Therapuetics with Phase II Emphasis$1,247,914
N01 · FY2010 · CA · contact PI
EARLY PHASE I AND II CLINICAL TRIALS IN PUERTO RICO$0
P20 · FY2002 · CA
CORE--CLINICAL TRIALS FACILITY$0
P01 · FY2002 · CA
DRUG SEQUENCING/RESISTANCE IN HEMATOLOGIC MALIGNANCIES$0
P01 · FY2002 · CA
DRUG SEQUENCING/RESISTANCE IN HEMATOLOGIC MALIGNANCIES$0
P01 · FY2001 · CA
EARLY PHASE I AND II CLINICAL TRIALS IN PUERTO RICO$0
P20 · FY2001 · CA
CORE--CLINICAL TRIALS FACILITY$0
P01 · FY2001 · CA
CORE--CLINICAL TRIALS FACILITY$0
P01 · FY2000 · CA
DRUG SEQUENCING/RESISTANCE IN HEMATOLOGIC MALIGNANCIES$0
P01 · FY2000 · CA